Executive Summary
IBM and Croga Innovations settled their dispute over U.S. Patent 10,601,780 and jointly moved to terminate the inter partes review, citing statutory authority under 35 U.S.C. §317.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in International Business Machines Corporation vs Croga Innovations Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Ascentcare Dental Products, Inc.vsSolmetex, LLC
Ascentcare Dental Products has filed a post‑grant review petition seeking cancellation of all 31 claims of Solmetex’s dental mouthpiece patent, alleging obviousness, lack of written description, and indefiniteness. The petition leans on three earlier patents and expert testimony to argue the claims are unpatentable.
Xencor, Inc.vsMerus N.V.
Xencor has filed an IPR petition challenging all seven claims of Merus’s ’859 bispecific antibody patent, asserting anticipation by Desjarlais and Moore and obviousness over Lazar and Kannan. The petitioner seeks institution and a finding that the claims are unpatentable.
Aylo Freesites Ltd et al.vsDISH Technologies L.L.C. et al.
The PTAB denied institution of an IPR petition filed by Aylo Freesites Ltd against DISH Technologies L.L.C., citing failure to demonstrate reasonable diligence in prior art search and tactical delays. The Board relied on General Plastic factors, finding the overlap between petitions was significant and Petitioner failed to justify its timing or discovery efforts regarding new references.
Abbott Diabetes Care Inc. et al.vsDexCom, Inc.
Abbott Diabetes Care and DexCom settled their IPR dispute over U.S. Patent 9,801,541, filing a joint motion that led the PTAB to terminate the proceeding and keep the settlement agreement confidential.
BOE Technology Group Co., Ltd.vsOptronic Sciences LLC
BOE Technology Group Co., Ltd. successfully petitioned to institute an IPR against Optronic Sciences LLC's patent, leading to a trial decision. The Board found reasonable likelihood of prevailing regarding at least one challenged claim (5-9).
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.